{"id":7915,"date":"2025-09-03T04:56:17","date_gmt":"2025-09-03T04:56:17","guid":{"rendered":"https:\/\/medical-article.com\/?p=7915"},"modified":"2025-09-03T04:56:17","modified_gmt":"2025-09-03T04:56:17","slug":"formulary-restrictions-and-health-outcomes-a-case-study-in-multiple-sclerosis","status":"publish","type":"post","link":"https:\/\/medical-article.com\/?p=7915","title":{"rendered":"Formulary restrictions and health outcomes: A case study in multiple sclerosis"},"content":{"rendered":"<p>How does formulary restrictions impact health outcomes for patients with multiple sclerosis (MS)?  To answer this question, <a href=\"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837127\">Blaylock, Van Nuys and Joyce (2025)<\/a> use data 100% Medicare claims data from 2018-2022 covering patients with both prescription drug plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs).  Individuals were categorized as above vs. below average formulary breadth depending on how many disease modifying therapies (DMTs) were covered.  Outcomes of interest include the rate of MS relapse.<\/p>\n<p>Using this approach, the authors found that: <\/p>\n<p>Oral or injectable MS DMTs were frequently excluded from coverage (&gt;50% excluded in 2022: PDPs,\u200911 of 15 DMTs; MA-PD, 9 of 15 DMTs). The MS relapse rate was greater for low- vs high-coverage PDPs (10.6% vs 9.5%; odds ratio [OR],\u20090.88 [95% CI, 0.84-0.92]) and MA-PDs (7.8% vs 6.9; OR, 0.88 [95% CI, 0.85-0.91]). In multivariable analyses, broader formulary coverage during baseline was associated with less MS relapse during follow-up (PDP: adjusted OR,\u20090.93 [95% CI, 0.90-0.96] for drugs and 0.94 [95% CI, 0.91-0.97] for classes; MA-PD: adjusted OR, 0.88 [95% CI, 0.83-0.94] for drugs and 0.92 [95% CI, 0.86-0.98] for classes). <\/p>\n<p>You can read the full paper <strong><a href=\"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837127\">here<\/a><\/strong>.<\/p>","protected":false},"excerpt":{"rendered":"<p>How does formulary restrictions impact health outcomes for patients with multiple sclerosis (MS)? To answer this question, Blaylock, Van Nuys and Joyce (2025) use data 100% Medicare claims data from 2018-2022 covering patients with both prescription drug plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs). Individuals were categorized as above vs. below average formulary&#8230;<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-7915","post","type-post","status-publish","format-standard","hentry","category-articles"],"_links":{"self":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts\/7915"}],"collection":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7915"}],"version-history":[{"count":0,"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts\/7915\/revisions"}],"wp:attachment":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}